Shanghai Pharma reports robust half-year growth, strategic advancements

Shanghai Pharmaceuticals Holding reported a 1.56% increase in operating revenue to RMB 141.6bn for the first half of 2025, with net profit attributable to shareholders surging by 51.56% to RMB 4.46bn. This growth was primarily driven by the acquisition of a 10% stake in Shanghai H&H Pharmaceuticals, increasing the total shareholding to 60% and consolidating its financial results. The company continued its focus on R&D, investing RMB 1.15bn in various drug pipelines and optimizing its research management system, with research expenses amounting to RMB 958.9m.

The company also emphasized its industrial transformation, actively managing its marketing efforts and implementing cost-reduction measures. Operating income for pharmaceutical industry sales was RMB 12.16bn and for commercial sales was RMB 129.56bn. Shanghai Pharmaceuticals continues to expand its "Great Health OTC + New Retail" strategy and has progressed in digital transformation across its pharmaceutical commercial operations.

Shanghai Pharmaceuticals Holding’s finance company reported total assets of RMB 898.6bn and net profit of RMB 28.09bn, meeting all regulatory indicators, including a capital adequacy ratio of 22.04% and a liquidity ratio of 46.39%. This indicates robust financial health and effective risk management across the group.